Presentation is loading. Please wait.

Presentation is loading. Please wait.

Date of download: 6/25/2016 From: Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic.

Similar presentations


Presentation on theme: "Date of download: 6/25/2016 From: Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic."— Presentation transcript:

1 Date of download: 6/25/2016 From: Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan Ann Intern Med. 1999;131(3):174-181. doi:10.7326/0003-4819-131-3-199908030-00003 Schema for patient selection. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

2 Date of download: 6/25/2016 From: Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan Ann Intern Med. 1999;131(3):174-181. doi:10.7326/0003-4819-131-3-199908030-00003 Cumulative incidence of hepatocellular carcinoma (HCC) among patients treated with interferon (solid line) and untreated patients (dotted line).P< 0.001 by the log-rank test. The number of hepatocellular carcinoma events and patients at risk at each time point are shown below the graph. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

3 Date of download: 6/25/2016 From: Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan Ann Intern Med. 1999;131(3):174-181. doi:10.7326/0003-4819-131-3-199908030-00003 Cumulative incidence of hepatocellular carcinoma (HCC) among patients treated with interferon (solid line) and untreated patients (dotted line), stratified by stage of liver fibrosis. Top left.PTop right.PBottom left.PBottom right.PPPatients with stage F0 or F1 fibrosis. > 0.2. Patients with stage F2 fibrosis. = 0.0128. Patients with stage F3 fibrosis. = 0.0011. Patients with stage F4 fibrosis. = 0.0573. All values were obtained by using the log-rank test. The number of hepatocellular carcinoma events and patients at risk at each time point are shown below each graph. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians


Download ppt "Date of download: 6/25/2016 From: Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic."

Similar presentations


Ads by Google